Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06230770

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California San Diego

San Diego, California, 92037, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English-speaking currently have a uterus and ovaries
  • desire to initiate GATT
  • potential desire to initiate a progestin (within 14 days of GATT initiation)

Exclusion criteria

  • previous gender-affirming surgery to remove their uterus and/or ovaries

Treatment and study plan

Bleeding data

Behavioral

Participants will report their daily bleeding patterns

Primary outcomes

  1. Mean days bleeding or spotting

    Time frame: Start of GATT to 30 days

    mean number of days of bleeding or spotting during the 30 days after GATT initiation

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Registry information

Official study title

The Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating Testosterone Therapy for Gender Affirmation

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jan 30, 2024
Registry last updated
Jul 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.